Search results for "media"

showing 10 items of 27073 documents

New microRNA Biomarkers for Drug-Induced Steatosis and Their Potential to Predict the Contribution of Drugs to Non-alcoholic Fatty Liver Disease

2017

Background and Aims: Drug-induced steatosis is a major reason for drug failure in clinical trials and post-marketing withdrawal; and therefore, predictive biomarkers are essential. These could be particularly relevant in non-alcoholic fatty liver disease (NAFLD), where most patients show features of the metabolic syndrome and are prescribed with combined chronic therapies, which can contribute to fatty liver. However, specific biomarkers to assess the contribution of drugs to NAFLD are lacking. We aimed to find microRNAs (miRNAs) responsive to steatotic drugs and to investigate if they could become circulating biomarkers for drug induced steatosis. Methods: Human HepG2 cells were treated wi…

0301 basic medicineDrugFarmacologiaMicroarraymedia_common.quotation_subjectBiologyPharmacology03 medical and health scienceshepatosteatosisCyclosporin amedicinePharmacology (medical)predictive biomarkermedia_commonOriginal ResearchPharmacologyFenofibratemicroRNAFatty livernon-alcoholic fatty liver diseasemedicine.diseasePatologiadrug-induced steatosis030104 developmental biologymetabolic syndrome drugDroguesSteatosisMetabolic syndromeTamoxifenmedicine.drugFrontiers in Pharmacology
researchProduct

Exercise training as a drug to treat age associated frailty

2016

Exercise causes an increase in the production of free radicals [1]. As a result of a hormetic mechanism antioxidant enzymes are synthesised and the cells are protected against further oxidative stress. Thus, exercise can be considered as an antioxidant [2]. Age-associated frailty is a major medical and social concern as it can easily lead to dependency. In this review we describe that oxidative stress is associated with frailty and the mechanism by which exercise prevents age-associated frailty. We propose that individually tailored multicomponent exercise programmes are one of the best ways to prevent and to treat age-associated frailty.

0301 basic medicineDrugGerontologyAgingmedicine.medical_specialtyRos signallingFree Radicalsmedia_common.quotation_subjectmedicine.disease_causeBiochemistry03 medical and health sciencesPhysiology (medical)HumansMedicineIntensive care medicineExercisemedia_commonFrailtybusiness.industryMechanism (biology)TOR Serine-Threonine KinasesHormesisMitochondriaOxidative Stress030104 developmental biologybusinessOxidative stressFree Radical Biology and Medicine
researchProduct

Functional characterization of circulating tumor cells (CTCs) from metastatic ER+/HER2− breast cancer reveals dependence on HER2 and FOXM1 for endocr…

2021

Simple Summary Acquired endocrine resistance and late recurrence in patients with ER+/HER2− breast cancer are complex and not fully understood. Here, we evaluated mechanisms of acquired resistance in circulating tumor cells (CTCs) from an ER+/HER2− breast cancer patient who initially responded but later progressed under endocrine treatment. We found a switch from ERα-dependent to HER2-dependent and ERα-independent expression of FOXM1, which may enable disseminated ER+/HER2− cells to re-initiate tumor cell growth and metastasis formation in the presence of endocrine treatment. We found that NFkB signaling sustains HER2 and FOXM1 expression in CTCs in the presence of ERα inhibitors suggesting…

0301 basic medicineDrugLife sciences; biologyCancer Researchmedia_common.quotation_subjectTumor cellslcsh:RC254-282Article03 medical and health sciencesTherapeutic approach0302 clinical medicineCirculating tumor cellBreast cancerHER2-dependent FOXM1 expressionddc:570ER+/HER2− circulating tumor cellsMedicineEndocrine systemskin and connective tissue diseasesmedia_commonER+/HER2��� circulating tumor cellsbusiness.industryendocrine therapy resistancelcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncologyApoptosis030220 oncology & carcinogenesisFOXM1Cancer researchbusiness
researchProduct

Metabolic activation and drug-induced liver injury:in vitroapproaches for the safety risk assessment of new drugs

2015

Drug-induced liver injury (DILI) is a significant leading cause of hepatic dysfunction, drug failure during clinical trials and post-market withdrawal of approved drugs. Many cases of DILI are unexpected reactions of an idiosyncratic nature that occur in a small group of susceptible individuals. Intensive research efforts have been made to understand better the idiosyncratic DILI and to identify potential risk factors. Metabolic bioactivation of drugs to form reactive metabolites is considered an initiation mechanism for idiosyncratic DILI. Reactive species may interact irreversibly with cell macromolecules (covalent binding, oxidative damage), and alter their structure and activity. This r…

0301 basic medicineDrugLiver injuryIdiosyncrasyMechanism (biology)media_common.quotation_subjectMetaboliteCellPharmacologyBiologyToxicologymedicine.diseaseIn vitro03 medical and health scienceschemistry.chemical_compound030104 developmental biologymedicine.anatomical_structureDrug developmentchemistrymedicinemedia_commonJournal of Applied Toxicology
researchProduct

Abacavir Induces Arterial Thrombosis in a Murine Model.

2018

Background The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs, making the profile of experimental actions demonstrated by abacavir compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking. Methods The present study appraised the effects of abacavir in a well-validated animal model of arterial thrombosis. The role of ATP-P2X7 receptors in the actions of the drug was also assessed, and the actions of recognized vascular-damaging agents and other nucleoside reverse-transcriptase inhibitors (NRTIs) were evaluated and compared to those of abacavir. Results Abacavir dose-dependently promoted thrombu…

0301 basic medicineDrugMaleAnti-HIV Agentsmedia_common.quotation_subject030204 cardiovascular system & hematologyPharmacologyProinflammatory cytokine03 medical and health sciences0302 clinical medicineimmune system diseasesAbacavirmedicineImmunology and AllergyAnimalsRofecoxibmedia_commonMice KnockoutDose-Response Relationship Drugbusiness.industryPurinergic receptorAntagonistvirus diseasesThrombosisPurinergic signallingmedicine.diseaseThrombosisDideoxynucleosidesDisease Models Animal030104 developmental biologyInfectious DiseasesReceptors Purinergic P2X7businessmedicine.drugThe Journal of infectious diseases
researchProduct

Mothering under the influence: How perinatal drugs of abuse alter the mother-infant interaction

2018

AbstractAlthough drug-abusing women try to moderate their drug and alcohol use during pregnancy, they often relapse at a time when childcare needs are high and maternal bonding is critical to an infant’s development. In the clinical setting, the search for the neural basis of drug-induced caregiving deficits is complex due to several intervening variables. Rather, the preclinical studies that control for drug dose and regimen, as well as for gestational and postpartum environment, allow a precise determination of the effects of drugs on maternal behaviour. Given the relevance of the issue, this review will gather reports on the phenotypic correlates of maternal behaviour in preclinical stud…

0301 basic medicineDrugMalecannabiSubstance-Related Disordersmedia_common.quotation_subjectMother infantcocainePrenatal Exposure Delayed EffectMaternal behaviourNicotine03 medical and health sciences0302 clinical medicinePregnancymedicineHumansMaternal Behaviormedia_commonPregnancymaternal behaviourbiologybusiness.industryalcoholGeneral Neurosciencestimulantperinatal substance usemedicine.diseasebiology.organism_classificationSubstance-Related DisorderMother-Child RelationsopiateRegimen030104 developmental biologyPrenatal Exposure Delayed EffectsSettore BIO/14 - FarmacologiaGestationFemaleCannabisbusiness030217 neurology & neurosurgeryClinical psychologymedicine.drugnicotineHuman
researchProduct

Need for Deprescribing in Hospital Elderly Patients Discharged with a Limited Life Expectancy: The REPOSI Study

2019

<b><i>Objective:</i></b> Older people approaching the end of life are at a high risk for adverse drug reactions. Approaching the end of life should change the therapeutic aims, triggering a reduction in the number of drugs.<b><i></i></b>The main aim of this study is to describe the preventive and symptomatic drug treatments prescribed to patients discharged with a limited life expectancy from internal medicine and geriatric wards. The secondary aim was to describe the potentially severe drug-drug interactions (DDI). <b><i>Materials and Methods:</i></b> We analyzed Registry of Polytherapies Societa Italiana di Medicina I…

0301 basic medicineDrugMalemedicine.medical_specialtyDeprescriptions020205 medical informaticsDrug-Related Side Effects and Adverse Reactionsmedia_common.quotation_subjectElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medications; Aged 80 and over; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Male; Polypharmacy; Deprescriptions; Life Expectancy; Patient DischargeSocio-culturale02 engineering and technology03 medical and health sciencesElderly · End of life · Limited life expectancy · Polypharmacy · Symptomatic medicationsPharmacotherapyDeprescriptionsLife ExpectancyElderlySymptomatic medications0202 electrical engineering electronic engineering information engineeringmedicine80 and overHumansLS4_4Medical prescriptionElderly; End of life; Limited life expectancy; Polypharmacy; Symptomatic medicationsmedia_commonAgedPolypharmacyAged 80 and overOriginal Paperbusiness.industryGeneral MedicineElderly End-of-life Limited life expectancy Polypharmacy Preventing medications Symptomatic medicationsElderly End of life Limited life expectancy Polypharmacy Symptomatic medicationsPatient DischargeClonidineLimited life expectancyItalyEmergency medicineEnd of lifeLife expectancyPolypharmacyFemale030101 anatomy & morphologyDeprescribingbusinessmedicine.drugSymptomatic medication
researchProduct

Plasmonic Nanosensors for the Determination of Drug Effectiveness on Membrane Receptors.

2016

We demonstrate the potential of the NanoSPR (nanoscale surface plasmon resonance sensors) method as a simple and cheap tool for the quantitative study of membrane protein–protein interactions. We use NanoSPR to determine the effectiveness of two potential drug candidates that inhibit the protein complex formation between FtsA and ZipA at initial stages of bacterial division. As the NanoSPR method relies on individual gold nanorods as sensing elements, there is no need for fluorescent labels or organic cosolvents, and it provides intrinsically high statistics. NanoSPR could become a powerful tool in drug development, drug delivery, and membrane studies.

0301 basic medicineDrugMaterials sciencemedia_common.quotation_subjectNanotechnologyCell Cycle Proteins02 engineering and technology03 medical and health sciencesBacterial ProteinsNanosensorEscherichia coliGeneral Materials ScienceSurface plasmon resonancePlasmonmedia_commonEscherichia coli ProteinsSurface Plasmon Resonance021001 nanoscience & nanotechnologyNanostructuresCytoskeletal Proteins030104 developmental biologyMembraneDrug developmentDrug deliveryFtsA0210 nano-technologyCarrier ProteinsProtein BindingACS applied materialsinterfaces
researchProduct

Shikonin derivatives for cancer prevention and therapy.

2019

Abstract Phytochemicals gained considerable interest during the past years as source to develop new treatment options for chemoprevention and cancer therapy. Motivated by the fact that a majority of established anticancer drugs are derived in one way or another from natural resources, we focused on shikonin, a naphthoquinone with high potentials to be further developed as preventive or therapeutic drug to fight cancer. Shikonin is the major chemical component of Lithospermum erythrorhizon (Purple Cromwell) roots. Traditionally, the root extract has been applied to cure dermatitis, burns, and wounds. Over the past three decades, the anti-inflammatory and anticancer effects of root extracts, …

0301 basic medicineDrugModels MolecularCancer Researchmedicine.medical_treatmentmedia_common.quotation_subject03 medical and health sciencesStructure-Activity Relationship0302 clinical medicineNeoplasmsMedicineAnimalsHumansmedia_commonCancer preventionTraditional medicinebiologybusiness.industryCancerImmunotherapyLithospermum erythrorhizonbiology.organism_classificationmedicine.diseaseAntineoplastic Agents PhytogenicClinical trialRadiation therapy030104 developmental biologyOncologyPhytochemical030220 oncology & carcinogenesisbusinessDrugs Chinese HerbalNaphthoquinonesCancer letters
researchProduct

Kinase Inhibitors in Multitargeted Cancer Therapy

2017

The old-fashioned anticancer approaches, aiming in arresting cancer cell proliferation interfering with non-specific targets (e.g. DNA), have been replaced, in the last decades, by more specific target oriented ones. Nonetheless, single-target approaches have not always led to optimal outcomes because, for its complexity, cancer needs to be tackled at various levels by modulation of several targets. Although at present, combinations of individual single-target drugs represent the most clinically practiced therapeutic approaches, the modulation of multiple proteins by a single drug, in accordance with the polypharmacological strategy, has become more and more appealing. In the perspective of…

0301 basic medicineDrugNiacinamideIndolesPyridinesmedia_common.quotation_subjectPharmacologyBioinformaticsBiochemistryReceptor tyrosine kinase03 medical and health sciencesCrizotinibPiperidinesMultitargeted drugs anticancer agents polypharmacology tyrosine kinase receptors oncogene addiction tumor microenvironment FDA-approved drugsNeoplasmsDrug DiscoverymedicineSunitinibHumansAnilidesPyrrolesProtein Kinase Inhibitorsmedia_commonPharmacologyTumor microenvironmentbiologybusiness.industryPhenylurea CompoundsOrganic ChemistryImidazolesCancerReceptor Protein-Tyrosine KinasesSorafenibmedicine.diseaseOncogene AddictionSettore CHIM/08 - Chimica FarmaceuticaClinical trialPyridazines030104 developmental biologyMechanism of actionbiology.proteinImatinib MesylateQuinazolinesMolecular MedicinePyrazolesmedicine.symptombusinessTyrosine kinase
researchProduct